Major drug companies and smaller biopharmaceutical companies have expended enormous amounts of effort and capital toward the development of new drugs to treat cardiovascular disease (CVD). Decision Resources, Inc., announces the publication of Next-Generation Cardiovascular Therapeutics: An Analysis of Key Biopharmaceutical Competitor Pipelines, a new DR Report that examines the current state of CVD drug discovery and development pipelines, with a special focus on eight biopharmaceutical companies at the forefront of developments in the CVD arena.
Biopharmaceutical companies are playing an increasingly important role in the discovery and development of drugs for CVD. The market for statins, antihypertensives, and other major cardiovascular drugs is relatively mature, and new and different concepts in CVD therapeutics are needed to meet the major unmet needs in this area. Many of these new ideas, represented by early- stage drugs and target discovery research, come from biopharmaceutical and genomics companies and from academia. Big Pharma companies, in addition to their own in-house efforts, are increasingly utilizing alliances with these smaller companies in order to fill their CVD pipelines.
Despite a dramatic decline in mortality over the last 20 years, CVD remains the leading cause of death in industrialized nations. In search of better solutions, many researchers are focusing on the pathophysiology of atherosclerosis, coronary artery disease (CAD), congestive heart failure (CHF), restenosis, and other cardiovascular conditions. Much of this research is centered on endothelial cell function and dysfunction at the level of cellular and molecular biology. Another major approach is based on the hypothesis that atherosclerosis and CAD are inflammatory diseases. The most immediate results of these two strategies have been the development of angiotensin-converting enzyme (ACE) inhibitors as cardioprotective agents in patients at high risk of coronary events and the emergence of C-reactive protein as a putative marker of risk for coronary events.
The companies profiled in this report are Actelion, COR Therapeutics, CV Therapeutics, Interleukin Genetics, Millennium Pharmaceuticals, Scios, Texas Biotechnology, and 3-Dimensional Pharmaceuticals. Our examination of these companies covers significant alliances, patent positions, developmental pipelines, and competitive assessments.
Next-Generation Cardiovascular Therapeutics: An Analysis of Key Biopharmaceutical Competitor Pipelines is a DR Report published by Decision Resources, Inc. This report is available for $4,250.00.
Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at http://www.dresources.com/.
Contact Tim Daley, 781.296.2636 (tel), 781.296.2525 (fax), or firstname.lastname@example.org. In Europe, contact Francoise Bidart, +32.2.351.4082 (tel), +32.2.351.2347 (fax), or email@example.com. In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (tel), +81.3.5401.2617 (fax), or firstname.lastname@example.org.
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840
SOURCE: Decision Resources, Inc.
Contact: Tim Daleyof of Decision Resources, Inc., +1-781-296-2636,